HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The emerging role of carfilzomib combination therapy in the management of multiple myeloma.

Abstract
Carfilzomib is a proteasome inhibitor that selectively and irreversibly binds to its target, resulting in sustained inhibition absent of off-target effects relative to bortezomib. Single-agent carfilzomib has produced robust and durable responses in clinical trials and it has been approved in the US for treating relapsed and refractory multiple myeloma (MM). Due to its favorable safety profile, carfilzomib is particularly suitable for use in combination strategies. Promising data have been reported from studies that investigated the use of carfilzomib in combination with immunomodulators, alkylating agents, glucocorticoids, histone deacetylase inhibitors and kinesin spindle protein inhibitors. Ongoing pivotal randomized Phase III studies are investigating the efficacy and safety of carfilzomib combinations in patients with relapsed MM and transplant ineligible patients.
AuthorsPhilippe Moreau
JournalExpert review of hematology (Expert Rev Hematol) Vol. 7 Issue 2 Pg. 265-90 (Apr 2014) ISSN: 1747-4094 [Electronic] England
PMID24521249 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Alkylating Agents
  • Glucocorticoids
  • Histone Deacetylase Inhibitors
  • Immunologic Factors
  • Oligopeptides
  • Proteasome Inhibitors
  • carfilzomib
Topics
  • Alkylating Agents (therapeutic use)
  • Clinical Trials as Topic
  • Drug Therapy, Combination
  • Glucocorticoids (therapeutic use)
  • Histone Deacetylase Inhibitors (therapeutic use)
  • Humans
  • Immunologic Factors (therapeutic use)
  • Multiple Myeloma (drug therapy)
  • Oligopeptides (therapeutic use)
  • Proteasome Inhibitors (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: